Re: At least RVX has a shorter trial timeline than ESPR

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: At least RVX has a shorter trial timeline than ESPR

in response to

Re: At least RVX has a shorter trial timeline than ESPR

Toinv

posted on May 05, 2016 05:42PM

Toniv,

Yes, apabetalone/RVX-208 is unique. It is the only BET inhibitor in clinical trials for something other than cancer. It is the only BET inhibitor in Phase 3 trials (I think one or two of the first generation BET inhibitors for cancer is entering Phase 2). It is the only bromodomain-2 selective BET inhibitor in clinical trials. That being said, it still needs to prove itself safe and effective in Phase 3 in a trial longer than 6 months and with a more narrow 3-point MACE. The ongoing BETonMACE will achieve this.